key: cord-0849224-fi42r1t2 authors: Ravula, Ushasree; Chunchu, Srinivasa Rao; Gente, Vikram Kumar title: WHOLE BLOOD DERIVED COVID CONVALESCENT PLASMA: An Economical option among Developing Countries date: 2021-01-02 journal: Transfus Apher Sci DOI: 10.1016/j.transci.2020.103045 sha: 55cd5109a986083d822c7737eebdd6234ffa1aca doc_id: 849224 cord_uid: fi42r1t2 nan To appear in: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. The Covid-19 disease has posed several challenges to the health care system across the world. This pandemic has affected nearly 220 countries as of date December 27, 2020 with an approximately 80 million people affected, 56 million recovered populations across the world and about 10 million affected and 9.7 million recovered cases in India 1 . With high rates of transmission of the disease and with no proven curative treatment available, health care systems across the world are severely overwhelmed. The covid-19 disease symptoms range from being asymptomatic, mild to moderate self-limiting respiratory tract illness to severe progressive pneumonia, multi-system involvement, multi-organ failure and death 2 . For treatment purposes various therapeutic agents are being explored, in addition to the standard supportive care including oxygen supply, intensive care admission, or even extracorporeal membrane oxygenation for critically ill patients 3 . Among therapeutic agents Antiviral Drugs, Antibacterials, Antimalarials, Monoclonal Antibodies, Corticosteroids are currently under evaluation for treatment of Covid-19 4 . Earliest studies of Seroprevalance of SARS-CoV-2 from various parts of the world was found to be: 2. The various studies showed increase in seroprevalence among general population as the blood donors as the SARS-CoV-2-disease expanded into the population. Yet the seroprevalence seems underestimated with disease expanding into the population. With rise in the number of cases and symptomatic cases, the seroprevalence in the general population and so in the donor population shall increase with time. The convalescent plasma can be whole blood derived convalescent plasma or obtained by apheresis technique which utilises equipment: cell separator and disposable kits. Whole blood derived Convalescent plasma requires an addition of SARS-CoV-2 antibody test to the existing mandatory tests, with no additional sampling requirement except for the ones done at the time of whole blood donation. From the donor units containing SARS-CoV-2-IgG antibodies, FFP can be segregated into Convalescent plasma inventory and stored for use in convalescent plasma therapy. Also heterogeneous units of plasma from at least two donors can be transfused for a single patient, to achieve therapeutic benefit in terms of immune protection from delivery of diverse antibodies 15 . Considering whole blood derived Convalescent plasma shall be an economical option for Convalescent Plasma Therapy in low and middle income countries where basic infrastructure for performing apheresis procedures are not available. Apheresis derived products are expensive, require technical expertise and recipient blood group matched donor. In view of ongoing pandemic, additional efforts by the Blood centres are needed to motivate apheresis donations, where the CP donors carry the fear of losing protective antibodies post donation. Now that the whole blood donations have stabilised Further, In similar lines of fractionation of plasma derived products like -immunoglobulins, albumin, factor V, VII, VIII concentrates, SARS-CoV-2 antibodies can also be extracted, lyophilised 16 and utilised as a plasma product with longer storage periods and ease of handling, which can even be supplied to remove areas with ease. With the second wave of Covid-19 and upcoming third wave along with other modalities of treatment, preparedness in terms of CP can be achieved by segregating Whole Blood derived FFP/plasma units with adequate SARS-CoV-2-antibody levels with addition of SARS-CoV-2 antibody test to the whole blood donations along with mandatory tests as per the country's regulations. Also, low prevalence blood group CP stock can be maintained. Whole blood derived Covid-Convalescent plasma is the best economical alternative option in low and middle income countries. Also reserves of Covid-convalescent plasma can be maintained with addition of SARS-CoV-2 antibody test to the whole blood donations unlike the Apheresis derived Convalescent plasma, which requires additional consumables like Cell separator machines, disposable kits, thereby limiting the bulk stock storage. COVID-19 Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19) A Review Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. The Lancet The current understanding and potential therapeutic options to combat COVID-19 Lower Prevalence of antibodies Neutralising SARS-CoV-2 in group O French Blood Donors Prevalence of SARS-CoV-2 in spain (ENE-COVID): A nation-wide, population based sero-epidemiological study Prevalence of antibodies to SARS-CoV-2 in Italian adults and associated risk factors High community SARS-CoV-2-antibody prevalence in Ski-Resort Community High seroprevalence of anti-SARS-VoV-2 antibodies in Chelsea Seroprevalence of SARS-CoV-2 antibodies among healthy blood donors in Karachi Treatment of Covid-19: old tricks for new challenges Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia The management of coronavirus infections with particular reference to SARS Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sanguis The chemistry of lyophilized blood products